


GE Healthcare

## Certificate of Facsimile Transmission

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being facsimile transmitted to the U.S. Patent and Trademark Office to Fax No. (571) 273-0791.

Melissa Leck  
Type or print name

  
Signature

March 9, 2005  
Date

## Fax Transmittal Cover Sheet

To Examiner Cynthia Wilder  
Art Unit: 1637

Fax (571) 273-0791

From Royal N. Ronning, Jr.  
Registration No.: 32,529  
(732) 457-8423

Date March 9, 2005

Number of pages including this one : 2

Re: United States Patent Application No.: 10/025,185  
Our docket no.: PU9989CIP2

Dear Examiner Wilder:

Further to our telephone conversation, please be advised that I hereby authorize the Commissioner to credit or debit any fees associated with the attached "Terminal Disclaimer to Obviate a Double Patenting Rejection Over a "Prior" Patent" number 6,664,061 to Applicant's deposit account number 502-590. Should you require any additional documentation, please do not hesitate to contact me.

Respectfully submitted:  
Royal N. Ronning, Jr.  
Attorney for Applicants

The information contained in this facsimile message is attorney/client privileged and confidential and is intended only for the use of the individual or entity named above. If the reader of this message is not the intended recipient, you are hereby notified that any dissemination, distribution, or copying of this communication is strictly prohibited. If you have received this communication in error, please immediately notify us by telephone and return the original message to us at the address depicted below via regular mail.

General Electric Company  
Amersham Biosciences Corp  
800 Centennial Avenue  
Piscataway, NJ 08854  
U.S.A.

T 732 457 8000  
F 732 457 8463



10025185  
03/10/2005 DJACBBS 00000006 502-590  
01 FC 014 130.00 DR

PTO/SB/26 (09-04)

Approved for use through 07/31/2006, OMB 0661-0031

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TERMINAL DISCLAIMER TO OBVIATE A DOUBLE PATENTING  
REJECTION OVER A "PRIOR" PATENT**

Docket Number (Optional)

PU0989CIP2

In re Application of: LIU, Chang-Gong, et al.

Application No.: 10/025,185

Filed: December 19, 2001

For: Hydrogel-Based Microarray Signal Amplification Methods and Devices Therefor

The owner\*, Amersham Biosciences AB, of 100 percent interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application which would extend beyond the expiration date of the full statutory term prior patent No. 6,664,061 as the term of said prior patent is defined in 35 U.S.C. 154 and 173, and as the term of said prior patent is presently shortened by any terminal disclaimer. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and the prior patent are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, the owner does not disclaim the terminal part of the term of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 and 173 of the prior patent, "as the term of said prior patent is presently shortened by any terminal disclaimer," in the event that said prior patent later:


- expires for failure to pay a maintenance fee;
- is held unenforceable;
- is found invalid by a court of competent jurisdiction;
- is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321;
- has all claims canceled by a reexamination certificate;
- is reissued, or
- is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.

Check either box 1 or 2 below, if appropriate.

1. ☐ For submissions on behalf of a business/organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the business/organization.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

2. ☒ The undersigned is an attorney or agent of record. Reg. No. 32,529

  
Signature

9 March 2005  
Date

Royal N. Renning, Jr.  
Typed or printed name

(732) 457-8423  
Telephone Number

- ☒ Terminal disclaimer fee under 37 CFR 1.20(d) included.

**WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2030.**

\*Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner).  
Form PTO/SB/96 may be used for making this certification. See MPEP § 324.

This collection of information is required by 37 CFR 1.321. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

11060 U.S. PTO  
12/19/01

12-26-01

A

Express Mail® mailing label number EL669269779US  
Date of Deposit December 19, 2001

Case No. 10907-5

# PATENT APPLICATION TRANSMITTAL LETTER

To the Commissioner for Patents:

Transmitted herewith for filing is the patent application of: Chang-Gong Liu for: HYDROGEL-BASED MICROARRAY SIGNAL

AMPLIFICATION METHODS AND DEVICES THEREFOR. Enclosed are:

- ☒ Three (3) sheet(s) of drawings, 33 pages of application (including title page).
- ☐ Declaration.
- ☐ Power of Attorney.
- ☐ Verified statement to establish small entity status under 37 CFR §§ 1.9 and 1.27.
- ☐ Assignment transmittal letter and Assignment of the invention to: \_\_\_\_\_.

Claims as Filed	Col. 1	Col. 2
No. Filed	No. Filed	No. Extra
Basic Fee		
Total Claims	67-20	47
Indep. Claims	4-3	1
Multiple Dependent Claims Present		

\*If the difference in col. 1 is less than zero, enter "0" in col. 2.

Small Entity	
Rate	Fee
	\$ 370
x\$9=	\$
x\$42=	\$
+\$140=	\$
Total	\$

Other Than Small Entity	
Rate	Fee
	\$ 740
47x\$18=	\$846
1x\$84=	\$84
+\$280=	\$
Total	\$1,670

- ☐ Please charge my Deposit Account No. 23-1925 in the amount of \$: \_\_\_\_\_. A duplicate copy of this sheet is enclosed.
- ☐ A check in the amount of \$: \_\_\_\_\_ to cover the filing fee is enclosed.
- ☐ The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 23-1925. A duplicate copy of this sheet is enclosed.
  - ☐ Any additional filing fees required under 37 CFR § 1.16.
  - ☐ Any patent application processing fees under 37 CFR § 1.17.
- ☒ The Commissioner is hereby authorized to charge payment of the following fees during the pendency of this application or credit any overpayment to Deposit Account No. 23-1925. A duplicate copy of this sheet is enclosed.
  - ☐ Any filing fees under 37 CFR § 1.16 for presentation of extra claims.
  - ☐ Any patent application processing fees under 37 CFR § 1.17.
  - ☐ The issue fee set in 37 CFR § 1.18 at or before mailing of the Notice of Allowance, pursuant to 37 CFR § 1.311(b).

Date

12/19/01

Jonathan M. Blanchard, Ph.D.  
BRINKS HOFER GILSON & LIONE  
Registration No. 48,927

Rev. Oct-01

F:\COMMON\jmbb\Common Client-Matter Documents\Fomal Papers by Case\10907 Motorola\10907-5\10907-5 Transmittal Letter.doc

11050 U.S. PTO  
10/025105  
12/19/01